

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 10-Q/A

EXPLANATORY NOTE

This Form 10-Q/A is being filed as Amendment No. 1 to the Form 10-Q of Introgen Therapeutics, Inc. ("Introgen") filed with the Securities and Exchange Commission on May 15, 2002 ("Form 10-Q") for the purpose of unredacting certain information in Exhibits 10.42 and 10.43 for which Introgen had previously sought confidential treatment. Except as set forth in this explanatory note, there are no changes to the Form 10-Q.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

INTROGEN THERAPEUTICS, INC.

Date: August 7, 2003

By: /s/ James W. Albrecht, Jr.

James W. Albrecht, Jr.
On behalf of the Registrant and as Chief
Financial Officer
(Principal Financial and Accounting Officer)

22

EXHIBIT INDEX

| EXHIBIT NUMBER ----- | DESCRIPTION ----- |
|----------------------------|--|
| 10.42+ | Series A Preferred Stock Purchase Agreement, effective as of March 7, 2002, by and among Introgen, VirRx, Inc. and certain stockholders of VirRx, Inc. |
| 10.43+ | Collaboration and License Agreement, effective as of March 7, 2002, by and between Introgen and VirRx, Inc. |

+ Confidential treatment has been requested for portions of this exhibit.